Science Market Update

Harvard and Merck Partner for $20M Cancer Therapeutics Research

Posted by Laura Braden on Mon, Apr 18, 2016

Acute myeloid leukemia (AML) is the most common form of leukemia affecting the blood and bone marrow, and has been responsible for 1.8% of cancer deaths in 2016. Because it is so prevalent, many research teams around the world study this disease in search of new treatment methods. One of these research teams, from Harvard University, has joined up with the pharmaceutical company Merck in a $20 million collaboration to develop new therapeutics for leukemia.

Read More

Tags: Harvard University, Northeast, Leukemia, cancer research, Massachusetts, Boston, BioResearch Product Faire Event, MA, Harvard, longwood, 2016, cancer therapy, Merck

Connect With Us   Like Us on Facebook   Follow Us on Twitter   See our latest photos!   Join Us on Google +   Find Us on LinkedIn   Pin our latest stories!

Subscribe to Company News